AJOVY is a prescription medicine used for the preventive treatment of migraine in adults.

**About AJOVY**
You’ve taken an important next step in your migraine treatment. The following may give you a better understanding of how AJOVY may help to prevent migraine.

In clinical trials, AJOVY was proven to reduce monthly migraine days by 50% or more.

AJOVY reduced migraine days by an average of 5 days a month (vs 3.2 days for placebo) in patients with chronic migraine (≥15 headache days a month) and reduced migraine days by an average of 3.5 days a month (vs 2.2 days for placebo) in patients with episodic migraine (<15 headache days a month) when taken quarterly or monthly over a 12-week period.

Additionally, 32% of patients with chronic migraine (vs 20% on placebo) and 46% of patients with episodic migraine (vs 28% on placebo) had their monthly migraine days reduced by at least 50% when taking either quarterly or monthly dosing regimens of AJOVY over a 12-week period.

AJOVY was shown to reduce migraine days, with some seeing results in as early as 1 week.

**IMPORTANT SAFETY INFORMATION**
Do not use AJOVY if you are allergic to AJOVY or any of the ingredients in AJOVY.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
AJOVY is the only anti-CGRP with the option of quarterly or monthly dosing to help prevent migraine*

**QUARTERLY**

4x per year
225 mg X 3 SC (subcutaneous)

Whether taken quarterly or monthly, AJOVY was shown to reduce monthly migraine days, with the potential to cut them by 50% or more.

**Ask your healthcare provider about your dosing options with AJOVY today.**

CGRP: calcitonin gene-related peptide

*Quarterly dosing is 675 mg administered as three 225 subcutaneous injections every three months. Monthly dosing is one 225 mg subcutaneous injection each month.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month after receiving AJOVY. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: swelling of your face, mouth, tongue, throat, or if you have trouble breathing. Talk to your doctor about stopping AJOVY if you have an allergic reaction.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
What are possible side effects of AJOVY?
The following side effects were reported by some patients included in AJOVY clinical trials, who were on either quarterly or monthly dosing.

AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month after receiving AJOVY. Adverse reactions reported by ≥2% of patients on AJOVY and greater than placebo were injection-site reactions, which were mostly mild to moderate.

2% or less of people discontinued AJOVY because of side effects.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of AJOVY. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Taking AJOVY

AJOVY comes in an autoinjector or a prefilled syringe. You can use AJOVY by yourself at home, or have it administered by your doctor in their office.

Follow these directions carefully, whether you take AJOVY quarterly or monthly. If you prefer to learn from a video, go to AJOVY.com. If you still have questions after reviewing these instructions or watching the instructional video, talk to your healthcare provider.

For subcutaneous injection only.

Read and follow the Instructions for Use that come with your AJOVY Autoinjector or AJOVY prefilled syringe before you start using it and each time you get a refill.

IMPORTANT SAFETY INFORMATION (CONTINUED)
Tell your healthcare provider about all the medicines you take, and if you are pregnant, planning to become pregnant, or are breastfeeding.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Important:
The AJOVY Autoinjector and prefilled syringe are for single-time (one-time) use only. After use, put the device in an FDA-approved sharps disposal container right away. Do not throw away the sharps disposal container in your household trash.

- Before injecting, let AJOVY sit at room temperature for 30 minutes. **Do not** warm up using a heat source such as hot water or a microwave.
- After you remove the needle cap from AJOVY, to prevent infection, **do not** touch the needle.
- **Do not** pull back on the plunger of the prefilled syringe at any time, as this can break the device.
- **Do not** inject AJOVY in your veins (intravenously).
- **Do not** re-use your autoinjector or prefilled syringe as this could cause injury or infection.
- **Do not** share your device with another person. You may give another person an infection or get an infection from them.
- You may give AJOVY yourself. If you feel uncomfortable, you should not get your first dose of AJOVY until you or your caregiver receive training from a healthcare provider on the right way to use AJOVY.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**
Common side effects of AJOVY include injection site reactions.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Storage Conditions:

- Make sure to keep AJOVY in the refrigerator between 36°F to 46°F (2°C to 8°C). Do not freeze.
- Keep AJOVY in the carton it comes in to protect it from light.
- If needed, AJOVY may be stored at room temperature between 68°F to 77°F (20°C to 25°C) in the carton it comes in for up to 24 hours. Do not use AJOVY if it has been out of the refrigerator for 24 hours or longer. Dispose of (throw away) AJOVY in a sharps disposal container if it has been out of the refrigerator for 24 hours or longer.
- **Do not** freeze. If AJOVY freezes, throw it away in a sharps disposal container.
- Keep AJOVY out of extreme heat and direct sunlight.
- **Do not** shake AJOVY.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of AJOVY. For more information, ask your healthcare provider or pharmacist.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
AJOVY® Autoinjector

AJOVY comes in an autoinjector. You can use the autoinjector by yourself at home, or have it administered by your healthcare provider in their office. If you prefer to learn from a video, go to AJOVY.com/autoinjector. For instructions on the AJOVY prefilled syringe, go to page 8.

How to use the AJOVY Autoinjector

These are not the complete instructions for using the AJOVY Autoinjector. Please read the full Instructions for Use in the Prescribing Information, starting on page 12, before administering AJOVY, and watch a video on how to use it at AJOVY.com/autoinjector.

Follow these directions whether you take AJOVY quarterly or monthly. To prepare for your injection, take your autoinjector out of the refrigerator. Make sure to wait 30 minutes until it reaches room temperature. Now you’re ready to follow the steps below.

Step 1: Uncap the autoinjector

With one hand, firmly pull the cap straight off the autoinjector (don’t twist) and throw the cap away immediately.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Step 2: Place at a 90° angle

Place the autoinjector at a 90° angle against your skin at your chosen injection site.

Step 3: Press down and hold the autoinjector until 10 seconds after second click

Press down on the autoinjector. You will hear a click. This means the injection has started and you should see the blue plunger move down. You will hear a second click. Remove the autoinjector 10 seconds after.

Please read the full Instructions for Use in the full Prescribing Information, starting on page 12, before administering AJOVY, and watch a video on how to use it at AJOVY.com/autoinjector.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
AJOVY Prefilled Syringe
You can use the prefilled syringe yourself at home, or have it administered by your healthcare provider in their office. If you prefer to learn from a video, go to AJOVY.com/prefilled-syringe. For instructions on the AJOVY Autoinjector, go to page 6.

How to use the AJOVY Prefilled Syringe
These are not the complete instructions for using the AJOVY prefilled syringe. Please read the full Instructions for Use in the Prescribing Information, starting on page 12, before administering AJOVY, and watch a video on how to use it at AJOVY.com/prefilled-syringe.

Follow these directions whether you take AJOVY quarterly or monthly. To prepare for your injection, take your prefilled syringe out of the refrigerator. Make sure to wait 30 minutes until it reaches room temperature. Now you’re ready to follow the steps below.

Step 1: Pick up the syringe

Pick up the body of the prefilled syringe with one hand and pull the needle cap straight off with your other hand. Do not shake or twist. Throw cap away immediately.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Choose an injection area, such as on your stomach, front of thighs, or back of upper arms. Clean the area with an alcohol swab.

Step 2: Select and prepare injection site

Step 3: Insert the needle at a 45° to 90° angle

Use your free hand to gently pinch up at least 1 inch of the injection site. Carefully insert the needle into pinched skin at a 45° to 90° angle.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Step 4: Slowly push the plunger all the way down

When the needle is all the way into your skin, use your thumb to slowly push the plunger down as far as it will go.

Step 5: Pull needle straight out, then apply gauze or cotton ball

After you have injected all of the medicine, pull the needle straight out, then apply gauze or a dry cotton ball on the site for a few seconds.

Please read the full Instructions for Use in the full Prescribing Information, starting on page 12, before administering AJOVY, and watch a video on how to use it at AJOVY.com/prefilled-syringe.

Please see Important Safety Information throughout and the accompanying Patient Information Leaflet in the full Prescribing Information beginning on page 12.
Need help or have questions about taking AJOVY? Contact our nurses. AJOVY may be administered by a healthcare professional, patient, or caregiver.

Nurse assistance
Call us today at 1-800-887-8100
Monday – Friday, 8 AM–6 PM CT

APPROVED USE
AJOVY is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION
Do not use AJOVY if you are allergic to AJOVY or any of the ingredients in AJOVY.

AJOVY may cause allergic reactions, including itching, rash, and hives that can happen within hours and up to 1 month after receiving AJOVY. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: swelling of your face, mouth, tongue, throat, or if you have trouble breathing. Talk to your doctor about stopping AJOVY if you have an allergic reaction.

Tell your healthcare provider about all the medicines you take, and if you are pregnant, planning to become pregnant, or are breastfeeding.

Common side effects of AJOVY include injection site reactions.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of AJOVY. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at 1-800-FDA-1088.

Please see Patient Information Leaflet in the full Prescribing Information on the following pages.
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
  2.1 Recommended Dosage
  2.2 Important Administration Instructions
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
  5.1 Hypersensitivity Reactions
6 ADVERSE REACTIONS
  6.1 Clinical Trials Experience
  6.2 Immunogenicity
8 USE IN SPECIFIC POPULATIONS
  8.1 Pregnancy
  8.2 Lactation
  8.3 Pediatric Use
  8.4 Geriatric Use
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
  12.1 Mechanism of Action
  12.2 Pharmacodynamics
  12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
15 HOW SUPPLIED/STORAGE AND HANDLING
16 PATIENT COUNSELING INFORMATION
17 REFERENCES

*Sections or subsections omitted from the full prescribing information are not listed.
6.2 Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underestimation. For these reasons, comparison of the incidence of antibodies to fremanezumab-vfrm in the studies described below with the incidence of antibodies in other studies to other products may be misleading. Clinical immunogenicity of AJOVY was monitored by analyzing anti-drug antibodies (ADA) and neutralizing antibodies in drug-treated patients. The data reflect the percentage of patients whose test results were positive for antibodies to AJOVY in specific assays.

In 3-month placebo-controlled studies, treatment-emergent ADA responses were observed in 6 out of 1701 (0.4%) AJOVY-treated patients. One of the 6 patients developed anti-AJOVY neutralizing antibodies at Day 84. In the ongoing long-term open-label study, 1/65 ADA were detected in 1.6% of patients (30 out of 1888). Out of 30 ADA-positive patients, 17 had a neutralizing activity in their post-dose samples. Although these data do not demonstrate an impact of anti-fremanezumab-vfrm antibody development on the efficacy or safety of AJOVY in these patients, the available data are too limited to make definitive conclusions.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no adequate data on the developmental risk associated with the use of AJOVY in pregnant women. AJOVY has a long half-life [see Clinical Pharmacology (12.3)]. This should be taken into consideration for women who are pregnant or plan to become pregnant during AJOVY. Administration of fremanezumab-vfrm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at doses resulting in plasma levels greater than those expected clinically did not result in adverse effects on development [see Animal Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated rate of major birth defects (2.2-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Clinical Considerations
Disease-Associated Maternal and/or Embryo/Fetal Risk
Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

Data
Animal Data
When fremanezumab-vfrm (0, 50, 100, or 200 mg/kg) was administered to male and female rats by weekly subcutaneous injection prior to and during mating and continuing in females throughout organogenesis, no adverse embryofetal effects were observed. The highest dose tested was associated with plasma exposures (AUC) approximately 2 times that in humans at a dose of 675 mg.

Administration of fremanezumab-vfrm (0, 10, 50, or 100 mg/kg) weekly by subcutaneous injection to pregnant rabbits throughout the period of organogenesis produced no adverse effects on embryofetal development. The highest dose tested was associated with plasma AUC approximately 3 times that in humans (675 mg).

Administration of fremanezumab-vfrm (0, 50, 100, or 200 mg/kg) weekly by subcutaneous injection to pregnant male rats throughout the period of organogenesis and lactation resulted in no adverse effects on pre- and postnatal development. The highest dose tested was associated with plasma AUC approximately 2 times that in humans (675 mg).

8.2 Lactation
Risk Summary
There is no data on the presence of fremanezumab-vfrm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AJOVY and any potential adverse effects on the breastfeeding infant from AJOVY or from the underlying maternal condition.

8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use
Clinical studies of AJOVY did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

11 DESCRIPTION
Fremanezumab-vfrm is a fully humanized IgG2a/kappa monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Fremanezumab-vfrm is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The antibody consists of 1524 amino acids and has a molecular weight of approximately 148 kDa. AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, colorless to slightly yellow solution for subcutaneous injection, supplied in a single-dose 225 mg/1.5 mL prefilled autoinjector and a single-dose 225 mg/1.5 mL prefilled syringe.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
AJOVY® (fremanezumab-vfrm) injection

Table 2: Efficacy Endpoints in Study 1

<table>
<thead>
<tr>
<th>Efficacy Endpoint</th>
<th>AJOVY 225 mg Monthly (N=287)</th>
<th>AJOVY 675 mg Quarterly (N=288)</th>
<th>Placebo (N=290)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monthly migraine days (MMD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline migraine days</td>
<td>8.9</td>
<td>9.2</td>
<td>9.1</td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-3.7</td>
<td>-3.4</td>
<td>-2.2</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-1.5</td>
<td>-1.2</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>≥50% MDD responders</td>
<td>47.7%</td>
<td>44.4%</td>
<td>27.9%</td>
</tr>
<tr>
<td>Monthly acute headache medication days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline</td>
<td>-3.0</td>
<td>-2.9</td>
<td>-1.6</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-1.4</td>
<td>-1.3</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1 displays the mean change from baseline in the average monthly number of migraine days in Study 1.

Figure 1: Change from Baseline in Monthly Migraine Days in Study 1

Figure 2 shows the distribution of change from baseline in mean monthly migraine days in Study 1. A treatment benefit over placebo for both doses of AJOVY is seen across a range of changes from baseline in migraine days.

Figure 2: Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 1

Table 3: Efficacy Endpoints in Study 2

<table>
<thead>
<tr>
<th>Efficacy Endpoint</th>
<th>AJOVY 225 mg Monthly (N=375)</th>
<th>AJOVY 675 mg Quarterly (N=375)</th>
<th>Placebo (N=371)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline headache days of any severity (^a)</td>
<td>20.3</td>
<td>20.4</td>
<td>20.3</td>
</tr>
<tr>
<td>Baseline headache days of at least moderate severity (^a)</td>
<td>12.8</td>
<td>13.2</td>
<td>13.3</td>
</tr>
<tr>
<td>Change from baseline in the monthly average number of headache days of at least moderate severity</td>
<td>-4.6</td>
<td>-4.3</td>
<td>-2.5</td>
</tr>
<tr>
<td>Difference from placebo</td>
<td>-2.1</td>
<td>-1.8</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Change from baseline in the monthly average number of migraine days in patients</td>
<td>-5.0</td>
<td>-4.9</td>
<td>-3.2</td>
</tr>
<tr>
<td>Change from baseline in monthly average number of headache days of at least moderate severity at 4 weeks after 1st dose</td>
<td>-4.6</td>
<td>-4.6</td>
<td>-2.3</td>
</tr>
<tr>
<td>Percentage of patients with ≥50% reduction in monthly average number of headache days of at least moderate severity</td>
<td>40.8%</td>
<td>37.6%</td>
<td>18.1%</td>
</tr>
<tr>
<td>Change from baseline in monthly average number of days of acute headache medication</td>
<td>-4.2</td>
<td>-3.7</td>
<td>-1.9</td>
</tr>
</tbody>
</table>

\(^a\) In Study 2, patients received a 675 mg starting dose.

Chronic Migraine

Study 2 (NCT 02621931) included adults with a history of chronic migraine (patients with ≥15 headache days per month). All patients were randomized (1:1:1) to receive subcutaneous injections of either AJOVY 675 mg starting dose followed by 225 mg monthly, 675 mg every 3 months (quarterly), or placebo monthly, over a 3-month treatment period. Patients were allowed to use acute headache treatments during the study. A subset of patients (21%) was allowed to use one additional concomitant, preventive medication.

The study excluded patients with a history of significant cardiovascular disease, vascular ischemia, or thrombotic events, such as cerebrovascular accident, transient ischemic attacks, deep vein thrombosis, or pulmonary embolism.

Figure 3 displays the mean change from baseline in the average monthly number of headache days of at least moderate severity in Study 2.

Figure 3: Change from Baseline in Monthly Headache Days of At Least Moderate Severity in Study 2

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period. The secondary endpoints were the mean change from baseline in the monthly average number of migraine days during the 3-month treatment period, the proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity during the 3-month treatment period, the mean change from baseline in the monthly average number of days of use of any acute headache medication during the 3-month treatment period, and the mean change from baseline in the number of headache days of at least moderate severity during the first month of treatment.

In Study 2, a total of 1130 patients (991 females, 139 males), ranging in age from 18 to 70 years, were randomized. A total of 1034 patients completed the 3-month double-blind phase.

Both monthly and quarterly dosing regimens of AJOVY treatment demonstrated statistically significant improvement for key efficacy outcomes compared to placebo, as summarized in Table 3.

Figure 4 shows the distribution of change from baseline in monthly headache days of at least moderate severity at month 3 in bins of 3 days by treatment group. A treatment benefit over placebo for both dosing regimens of AJOVY is seen across a range of changes from baseline in headache days.
Figure 4: Distribution of Mean Change from Baseline in Monthly Headache Days of At Least Moderate Severity by Treatment Group in Study 2

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Percentage of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (N=371)</td>
<td>10</td>
</tr>
<tr>
<td>AJOVY 675 mg Quarterly (N=287)</td>
<td>5</td>
</tr>
<tr>
<td>AJOVY 225 mg Monthly* (N=288)</td>
<td>2.5</td>
</tr>
</tbody>
</table>

Fewer headache days of at least moderate severity per month

*In Study 2, patients received a 675 mg starting dose.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous administration. AJOVY is not made with natural rubber latex.

AJOVY is supplied as follows:

Prefilled Autoinjector
- Pack of 1 autoinjector: 225 mg/1.5 mL single-dose prefilled autoinjector NDC 51759-202-10

Prefilled Syringe
- Pack of 1 syringe: 225 mg/1.5 mL single-dose prefilled syringe NDC 51759-204-10

16.2 Storage and Handling
- Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original outer carton to protect from light.
- If necessary, AJOVY may be kept in the original carton at room temperature up to 25°C (77°F) for a maximum of 24 hours. After removal from the refrigerator, AJOVY must be used within 24 hours or discarded.
- Do not freeze.
- Do not expose to extreme heat or direct sunlight.
- Do not shake.

17 PATIENT COUNSELING INFORMATION

Advising the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Information on Preparation and Administration

Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic technique, and how to use the single-dose prefilled syringe [see Dosage and Administration (2.2)]. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use AJOVY.

Instruct patients prescribed the regimen of 675 mg every 3 months to administer the dosage as three consecutive subcutaneous injections of 225 mg each [see Dosage and Administration (2.1)].

Hypersensitivity Reactions

Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur up to 1 month after administration. Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur [see Warnings and Precautions (5.1)].

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016
AJOVY® (fremanezumab-vfrm), its use, or its process of manufacture, may be protected by one or more United States patents, including US 8,007,794, US 8,586,045 and US 9,896,502.
©2020 Teva Pharmaceuticals USA, Inc.
AJO-004

What is AJOVY?
AJOVY is a prescription medicine used for the preventive treatment of migraine in adults.

It is not known if AJOVY is safe and effective in children.

Who should not use AJOVY?
Do not use AJOVY if you are allergic to fremanezumab-vfrm or any of the ingredients in AJOVY. See the end of this leaflet for a complete list of the ingredients in AJOVY.

Before you use AJOVY, tell your healthcare provider if you:
- are pregnant or plan to become pregnant. It is not known if AJOVY will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if AJOVY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using AJOVY.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine.

How should I use AJOVY?
- See the detailed “Instructions for Use” for information on how to prepare and inject a dose of AJOVY.
- Use AJOVY exactly as your healthcare provider tells you to use it.
- AJOVY is given by injection under your skin (subcutaneously).
- Your healthcare provider should show you or your caregiver how to prepare and inject your dose of AJOVY before you or your caregiver give your AJOVY the first time.
- Your healthcare provider will tell you how much AJOVY to use and when to use it.
  ◦ Your healthcare provider will tell you if you should use AJOVY 225 mg one time every month or AJOVY 675 mg one time every 3 months
  ◦ If your prescribed dose is AJOVY 675 mg every 3 months, you must use 3 separate autoinjectors or 3 separate syringes. You will give 3 separate injections one time every 3 months.
- If you are giving 3 injections of AJOVY for your prescribed dose, you may use the same injection area for all 3 injections, but not the same spot.
- Do not inject AJOVY in the same injection site that you inject other medicine.
- If you are switching from using AJOVY one time every month to one time every 3 months or if you are switching from using AJOVY one time every 3 months to one time every month, give the first dose of AJOVY on the day it was due to be given on your old schedule.
- If you miss a dose of AJOVY, take it as soon as possible. If you need to take the dose late, you will need to change your schedule: if you take 225 mg of AJOVY, inject your next dose 1 month after the late dose. If you take 675 mg of AJOVY, inject your next dose 3 months after the late dose. If you have questions about your schedule, ask your healthcare provider.

continued
What are the possible side effects of AJOVY?
AJOVY may cause serious side effects, including:

- **Allergic reactions.** Allergic reactions, including itching, rash, and hives, can happen within hours and up to 1 month after receiving AJOVY. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms of an allergic reaction:
  - swelling of your face, mouth, tongue, or throat
  - trouble breathing

The most common side effects of AJOVY include:

- injection site reactions
- Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
- These are not all the possible side effects of AJOVY. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store AJOVY?

- Store AJOVY in the refrigerator between 36°F to 46°F (2°C to 8°C).
- Keep AJOVY in the carton it comes in to protect from light.
- If needed, AJOVY may be stored at room temperature between 68°F to 77°F (20°C to 25°C) in the carton it comes in for up to 24 hours. Do not use AJOVY if it has been out of the refrigerator for 24 hours or longer. Throw away (dispose of) AJOVY in a sharps disposal or puncture-resistant container if it has been out of the refrigerator for 24 hours or longer.
- Do not freeze. If AJOVY freezes, throw it away in a sharps disposal container.
- Keep AJOVY out of extreme heat and direct sunlight.
- Do not shake AJOVY.

Keep AJOVY prefilled autoinjector and AJOVY prefilled syringe out of the reach of small children.

General information about the safe and effective use of AJOVY.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AJOVY for a condition for which it was not prescribed. Do not give AJOVY to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about AJOVY that is written for health professionals.

What are the ingredients in AJOVY?

**Active ingredient:** fremanezumab-vfrm

**Inactive ingredients:** disodium ethylenediaminetetraacetic acid dihydrate (EDTA), L-histidine, L-histidine hydrochloride monohydrate, polysorbate-80, sucrose, and Water for Injection.

AJOVY prefilled syringe and prefilled autoinjector are not made with natural rubber latex.

Manufactured by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454
US License No. 2016 AJOPL-003

For more information, go to www.AJOVY.com or call 1-888-483-8279.

This Patient Information has been approved by the U.S. Food and Drug Administration.

Revised: 1/2020
Read this before you inject.

Step 1. Check the dose your healthcare provider has prescribed.
AJOVY comes as a single-dose (one time) prefilled autoinjector. Your healthcare provider will prescribe the dose that is best for you.
- If your healthcare provider has prescribed 225 mg of AJOVY each month for you, give 1 injection each month, using a 225 mg prefilled AJOVY autoinjector.
- If your healthcare provider has prescribed 675 mg of AJOVY every 3 months for you, give 3 separate injections, one after another, using a different 225 mg prefilled AJOVY autoinjector for each injection. Give these injections 1 time every 3 months.

Before you inject, always check the label of your single-dose prefilled autoinjector to make sure you have the correct medicine and the correct dose of AJOVY. If you are not sure of your dose, ask your healthcare provider.

How do I inject AJOVY?
Step 2. Remove the prefilled autoinjector from the carton.
- You may need to use more than 1 prefilled autoinjector depending on your prescribed dose.
- Remove the autoinjector from the carton (see Figure C).
- Do not shake the prefilled autoinjector at any time, as this could affect the way the medicine works.

Figure C

Step 3. Gather the supplies you will need to inject AJOVY.
- Gather the following supplies (see Figure D) and the number of AJOVY 225 mg prefilled autoinjectors you will need to give your prescribed dose:
  - If your dose is 225 mg, you will need 1 AJOVY 225 mg prefilled autoinjector.
  - If your dose is 675 mg, you will need 3 AJOVY 225 mg prefilled autoinjectors.
  - Alcohol swabs (not supplied).
  - Gauze pads or cotton balls (not supplied).
  - Sharps disposal or puncture-resistant container (not supplied).

Figure D

Step 4. Let AJOVY reach room temperature.
- Place the supplies you have gathered on a clean, flat surface.
- Wait for 30 minutes to allow the medicine to reach room temperature.
- Do not leave the prefilled autoinjector in direct sunlight.
- Do not warm up the AJOVY prefilled autoinjector using a heat source such as hot water or a microwave.

Figure F

Step 5. Wash your hands.
- Wash your hands with soap and water and dry well with a clean towel. Be careful not to touch your face or hair after washing your hands.

Step 6. Look closely at your AJOVY prefilled autoinjector.
Note: You may see air bubbles in the prefilled autoinjector. This is normal. Do not remove the air bubbles from the prefilled autoinjector before giving your injection. Injecting AJOVY with these air bubbles will not harm you.

Figure E

Step 7: Choose your injection area.
- Choose an injection area from the following areas (see Figure F):
  - your stomach area (abdomen), avoid about 2 inches around the belly button.
  - the front of your thighs, an area that is at least 2 inches above the knee and 2 inches below the groin.
  - the back of your upper arms, in the fleshy area of the upper back portion.

Note: There are some injection areas on your body that are hard to reach (like the back of your arm). You may need help from someone who has been instructed on how to give your injection if you cannot reach certain injection areas.

Step 8. Clean your injection area.
- Clean the chosen injection area using a new alcohol swab. Let your skin dry.
- Do not inject AJOVY into an area that is tender, red, bruised, callused, tattooed, hard, or that has scars or stretch marks.
- Do not inject AJOVY in the same injection site that you inject other medicine.
- If you want to use the same injection area for the 3 separate injections needed for the 675 mg dose, make sure the second and third injections are not at the same spot you used for the other injections.
AJOVY® (fremanezumab-vfrm) injection

Instructions for Use

For subcutaneous injection only.
Read and follow the Instructions for Use for your AJOVY prefilled syringe before you start using it and each time you get a refill.

Important:
- AJOVY prefilled syringe is for single-time (one-time) use only. Put AJOVY in a FDA-cleared sharps disposal or puncture-resistant container right away after use. Do not throw away (dispose of) your used sharps disposal container in your household trash.
- Before injecting, let AJOVY sit at room temperature for 30 minutes.
- Keep AJOVY prefilled syringe out of the reach of small children.
- After you remove the needle cap from AJOVY, to prevent infection, do not touch the needle.
- Do not pull back on the plunger at any time, as this can break the prefilled syringe.

AJOVY® (fremanezumab-vfrm) injection

Step 9. Remove protective cap and do not replace.
• Pick up the prefilled autoinjector in 1 hand.
• Hold the prefilled autoinjector as shown in Figure G and pull the protective cap straight off with your other hand. Do not twist.
• Throw away the protective cap right away.
• Do not put the protective cap back on the prefilled autoinjector, to avoid injury and infection.

Figure G

Step 10. Give your injection.
• 10.1 Place the prefilled autoinjector at a 90 degree angle against your skin at the injection site you have cleaned (see Figure H).

Figure H

10.2 Press down on the prefilled autoinjector and keep holding it down against the skin for about 30 seconds. Do not remove pressure until the 3 steps below are complete.

1. You hear the first “click” (this means the injection has started and the blue plunger starts to move).
2. You hear a second “click” (about 15 seconds after the first click. The plunger will be moving to the bottom of the viewing window as the medicine is being injected.)
3. You wait another 10 seconds. (to make sure all the medicine is injected).

10.3 Check that the blue plunger has filled the viewing window and remove the autoinjector from the skin by lifting the prefilled autoinjector straight up (see Figure I).

Note: When the blue plunger has filled the viewing window you will be able to see the gray stopper.

As the prefilled autoinjector is lifted from the skin, the needle shield returns to the original (before use) position and locks into place, covering the needle.
Do not try to put the protective cap back on the used prefilled autoinjector as it is no longer needed.
Do not try to re-use the prefilled autoinjector.

Figure I

Step 11. Apply pressure to the injection site.
• Use a clean, dry cotton ball, or gauze pad to gently press on the injection site for a few seconds.
• Do not rub the injection site.
• Do not re-use the prefilled autoinjector.

Step 12. Dispose of your prefilled autoinjector right away.
• Put your used prefilled autoinjectors in a FDA-cleared sharps disposal container right away after use.
• Do not throw away (dispose of) prefilled autoinjectors in your household trash. Do not recycle your used sharps disposal container.
• If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  ◦ made of a heavy-duty plastic,
  ◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  ◦ upright and stable during use,
  ◦ leak-resistant, and
  ◦ properly labeled to warn of hazardous waste inside the container.
• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used autoinjectors. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal
• Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Injection Complete

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016
©2020 Teva Pharmaceuticals USA, Inc.
AJ0IFU-AI-002
Approved: 1/2020

Instructions for Use
AJOVY® (a-JO-vee)
(fremanezumab-vfrm) injection
prefilled syringe, for subcutaneous use

©2020 Teva Pharmaceuticals USA, Inc.
AJOVY® (fremanezumab-vfrm) injection

• Do not inject AJOVY in your veins (intravenously).
• Do not re-use your AJOVY prefilled syringe, as this could cause injury or infection.
• Do not share your AJOVY prefilled syringe with another person. You may give another person an infection or get an infection from them.

You may give AJOVY yourself. If you feel uncomfortable, you should not get your first dose of AJOVY until you or your caregiver receive training from a healthcare provider on the right way to use AJOVY.

Storage Conditions:
• Store AJOVY in the refrigerator between 36°F to 46°F (2°C to 8°C).
• Keep AJOVY in the carton it comes in to protect from light.
• If needed, AJOVY may be stored at room temperature between 68°F to 77°F (20°C to 25°C) in the carton it comes in for up to 24 hours. Do not use AJOVY if it has been out of the refrigerator for 24 hours or longer. Throw away (dispose of) AJOVY in a sharps disposal or puncture-resistant container if it has been out of the refrigerator for 24 hours or longer.
• Do not freeze. If AJOVY freezes, throw it away in a sharps disposal container.
• Keep AJOVY out of extreme heat and direct sunlight.
• Do not shake AJOVY.

AJOVY prefilled syringe (Before use). See Figure A.

AJOVY prefilled syringe (After use). See Figure B.

Read this before you inject.

Step 1. Check the dose your healthcare provider has prescribed. AJOVY comes as a single-dose (one time) prefilled syringe. Your healthcare provider will prescribe the dose that is best for you.
• If your healthcare provider has prescribed 225 mg of AJOVY each month for you, give 1 injection each month using a 225 mg prefilled AJOVY syringe.
• If your healthcare provider has prescribed 675 mg of AJOVY every 3 months for you, give 3 separate injections, one after another, using a different 225 mg prefilled AJOVY syringe for each injection. Give these injections 1 time every 3 months.

Before you inject, always check the label of your single-dose prefilled syringe to make sure you have the correct medicine and the correct dose of AJOVY. If you are not sure of your dose, ask your healthcare provider.

How do I inject AJOVY?

Step 2. Remove the prefilled syringe from the carton. You may need to use more than 1 prefilled syringe depending on your prescribed dose.
• Hold the prefilled syringe (as shown in Figure C).
• Remove the syringe from the carton.
• Do not shake the prefilled syringe at any time, as this could affect the way the medicine works.

Step 3. Gather the supplies you will need to inject AJOVY.
• Gather the following supplies (see Figure D) and the number of AJOVY 225 mg prefilled syringes you will need to give your prescribed dose:
  – If your dose is 225 mg, you will need 1 AJOVY 225 mg prefilled syringe.
  – If your dose is 675 mg, you will need 3 AJOVY 225 mg prefilled syringes.
  – alcohol swabs (not supplied).
  – gauze pads or cotton balls (not supplied).
  – sharps disposal or puncture-resistant container (not supplied).

Step 4. Let AJOVY reach room temperature.
• Place the supplies you have gathered on a clean, flat surface.
• Wait for 30 minutes to allow the medicine to reach room temperature.
• Do not leave the prefilled syringe in direct sunlight.
• Do not warm up the AJOVY prefilled syringe using a heat source such as hot water or a microwave.

Step 5. Wash your hands.
• Wash your hands with soap and water and dry well with a clean towel. Be careful not to touch your face or hair after washing your hands.

Step 6. Look closely at your AJOVY prefilled syringe.
Note: You may see air bubbles in the prefilled syringe. This is normal. Do not remove the air bubbles from the prefilled syringe before giving your injection. Injecting AJOVY with these air bubbles will not harm you.

• Check that the liquid medicine in the prefilled syringe is clear and colorless to slightly yellow before you give your injection (see Figure E). If the liquid has any particles in it, or is discolored, cloudy, or frozen, do not use the prefilled syringe. Call your healthcare provider or pharmacist.
• Do not use the prefilled syringe if it has any visible damage, such as cracks or leaks. See disposal instructions in Step 12.

• Check that AJOVY appears on the prefilled syringe.
• Do not use the prefilled syringe if it has been given the wrong medicine.

• Check the expiration date (EXP) printed on the prefilled syringe label.
• Do not use the prefilled syringe if the expiration date (EXP) has passed.
AJOVY® (fremanezumab-vfrm) injection

Step 7. Choose your injection area.
- Choose an injection area from the following areas (see Figure F):
  ◦ your stomach area (abdomen), avoid about 2 inches around the belly button.
  ◦ the front of your thighs, an area that is at least 2 inches above the knee and 2 inches below the groin.
  ◦ the back of your upper arms, in the fleshy area of the upper back portion.

Note: There are some injection areas on your body that are hard to reach (like the back of your arm). You may need help from someone who has been instructed on how to give your injection if you cannot reach certain injection areas.

Step 8. Clean your injection area.
- Clean the chosen injection area using a new alcohol swab. Let your skin dry.
- Do not inject AJOVY into an area that is tender, red, bruised, callused, tattooed, hard, or that has scars or stretch marks.
- Do not inject AJOVY in the same injection site that you inject other medicine.
- If you want to use the same injection area for the 3 separate injections needed for the 675 mg dose, make sure the second and third injections are not at the same spot you used for the other injections.

Step 9. Remove needle cap and do not replace.
- Pick up the body of the prefilled syringe with 1 hand.
- Pull the needle cap straight off with your other hand (see Figure G). Do not twist.
- Throw away the needle cap right away.
- Do not put the needle cap back on the prefilled syringe, to avoid injury and infection.

Step 10. Give your injection following the 4 steps below.
1. Use your free hand to gently pinch up at least 1 inch of the skin that you have cleaned.
2. Insert the needle into the pinched skin at a 45 to 90 degree angle.
3. When the needle is all the way into your skin, use your thumb to push the plunger.
4. Push the plunger slowly all the way down as far as it will go to inject all of the medicine.

Step 11. Remove the needle from your skin.
- After you have injected all of the medicine, pull the needle straight out (see Figure H).
- Do not recap the needle at any time to avoid injury and infection.

Step 12. Apply pressure to the injection site.
- Use a clean, dry cotton ball or gauze to gently press on the injection site for a few seconds.
- Do not rub the injection site.
- Do not re-use the prefilled syringe.

Step 13. Dispose of your prefilled syringe right away.
- Put your used prefilled syringes, needles, and sharps in a FDA-cleared sharps disposal container right away after use.
- Do not throw away (dispose of) loose needles, syringes, or prefilled syringes in your household trash. Do not recycle your used sharps disposal container.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  ◦ made of a heavy-duty plastic,
  ◦ can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  ◦ upright and stable during use,
  ◦ leak-resistant, and
  ◦ properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Injection Complete
This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016
©2020 Teva Pharmaceuticals USA, Inc.

teva
AJOIFU-PFS-003
Revised: 1/2020
FRE-42207